Ramalingam S, Ponnuswamy T K, Sivan Y S
Principal and Head, Department of Clinical Research and Bioethics, PSG Institute of Medical Sciences and Research, Avinashi Road, Peelamedu, Coimbatore 641 004 INDIA e-mail:
Indian J Med Ethics. 2013 Jul-Sep;10(3):190-1. doi: 10.20529/IJME.2013.055.
Adverse drug reactions (ADRs) have ethical implications. These include assessment of the risk-benefit ratio and re-administering informed consent based on the new ADRs identified. The Indian Council of Medical Research ethical guidelines mandate the scrutiny of ADR; and the standard operating procedures of the ethics committee of the authors' medical school endorse this line. However, institutional review board members are often hardpressed for time and are unable to analyse all the reported ADRs as thoroughly as required. This calls for a dedicated system for the scrutiny of ADRs. This paper seeks to share the experience of development and implementation of a review mechanism for ADR monitoring. The authors report an innovation in ADR monitoring by appointing a technical advisor on ADR (TA-ADR). During routine assessment, an unusual occurrence of ADRs was noticed from internal and external sites which were related to the study drug, which in turn resulted in the trial being put on hold. This system is being reported here for possible adoption by others.
药物不良反应(ADR)具有伦理意义。这些包括风险效益比的评估以及基于新发现的ADR重新进行知情同意。印度医学研究理事会的伦理准则要求对ADR进行审查;作者所在医学院伦理委员会的标准操作程序也支持这一点。然而,机构审查委员会成员往往时间紧迫,无法按要求对所有报告的ADR进行全面分析。这就需要一个专门的ADR审查系统。本文旨在分享ADR监测审查机制的开发与实施经验。作者报告了通过任命一名ADR技术顾问(TA - ADR)在ADR监测方面的一项创新。在常规评估期间,从内部和外部场所注意到与研究药物相关的ADR异常发生,这反过来导致试验被暂停。在此报告该系统,以供其他人可能采用。